Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) EBITDA Margin: 2015-2025

Historic EBITDA Margin for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to -732.75%.

  • Intellia Therapeutics' EBITDA Margin rose 70793.00% to -732.75% in Q3 2025 from the same period last year, while for Sep 2025 it was -778.95%, marking a year-over-year increase of 42225.00%. This contributed to the annual value of -895.50% for FY2024, which is 41667.00% up from last year.
  • Latest data reveals that Intellia Therapeutics reported EBITDA Margin of -732.75% as of Q3 2025, which was down 2.68% from -713.65% recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' EBITDA Margin peaked at 6,825.61% during Q4 2023, and registered a low of -23,935.00% during Q3 2021.
  • For the 3-year period, Intellia Therapeutics' EBITDA Margin averaged around -270.33%, with its median value being -780.13% (2023).
  • Per our database at Business Quant, Intellia Therapeutics' EBITDA Margin plummeted by 2,380,915bps in 2021 and then skyrocketed by 2,308,287bps in 2022.
  • Intellia Therapeutics' EBITDA Margin (Quarterly) stood at -651.12% in 2021, then slumped by 17,036bps to -821.48% in 2022, then soared by 764,710bps to 6,825.61% in 2023, then plummeted by 784,775bps to -1,022.14% in 2024, then surged by 70,793bps to -732.75% in 2025.
  • Its EBITDA Margin stands at -732.75% for Q3 2025, versus -713.65% for Q2 2025 and -684.89% for Q1 2025.